AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

3.760

+0.1704.74%

Volume:1.39M

Turnover:5.09M

Market Cap:1.40B

PE:-18.67

High:3.770

Open:3.610

Low:3.490

Close:3.590

52wk High:5.870

52wk Low:1.430

Shares:372.03M

Float Shares:274.26M

Volume Ratio:0.60

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.201

EPS(LYR):-0.201

ROE:-54.37%

ROA:-33.76%

PB:15.50

PE(LYR):-18.67

Loading ...

Overview Company News Filings

Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial

Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%

MT Newswires Live

Why Clarity Pharmaceuticals (ASX:CU6) Is Up 14.5% After Standout Phase II PSMA Imaging Results

Simply Wall St.

Clarity Pharmaceuticals (ASX:CU6) Valuation Check After New Co PSMA Abstract And Registrational Trial Progress

Simply Wall St.

Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial

Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial

MT Newswires Live

Clarity Pharmaceuticals Ltd's (ASX:CU6) market cap dropped AU$145m last week; individual investors who hold 48% were hit as were institutions

Simply Wall St.

Clarity Pharmaceuticals Posts Cash Position of AU$226.2 Million at End of December 2025 Quarter

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA

Clarity Pharmaceuticals' Prostate Cancer Trial to Continue Without Changes to Protocol

MT Newswires Live

Clarity Pharmaceuticals Co-PSMA Trial Results to Be Presented at EAU Congress 2026

Clarity Pharmaceuticals Plans Phase 3 Registrational Trial for Neuroendrocine Tumor Diagnostic Agent

MT Newswires Live

BUZZ-Australia's Clarity Pharma surges as US FDA approves trial

BRIEF-Clarity Pharmaceuticals To Commence Phase III Trial Of 64 Cu-Sartate In NETS

Clarity Pharmaceuticals Ltd - to Commence Phase Iii Trial of 64 Cu-Sartate in Nets

THOMSON REUTERS

BUZZ-Australia's Clarity Pharmaceuticals extends gains post Jefferies upgrade

Clarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies

MT Newswires Live

BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial

Jefferies Upgrades Clarity Pharmaceuticals to Buy From Hold; Price Target is AU$5

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CU6.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":3.76,"timestamp":1771996320000,"preClose":3.59,"halted":0,"volume":1391891,"delay":0,"changeRate":0.04735376044568243,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.201427,"marketStatus":"Closed","change":0.17,"latestTime":"02-25 16:12:00 AEDT","open":3.61,"high":3.77,"low":3.49,"amount":5090278,"amplitude":0.077994,"askPrice":3.76,"askSize":200,"bidPrice":3.74,"bidSize":2800,"shortable":3,"etf":0,"ttmEps":-0.201427,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1772060400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":3.59,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0.604467,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-33.76%","roe":"-54.37%","lyrEps":-0.201427,"volumeRatio":0.604467,"shares":372030071,"dividePrice":0,"high":3.77,"amplitude":0.077994,"preClose":3.59,"low":3.49,"week52Low":1.43,"pbRate":"15.50","psRate":"147.82","week52High":5.87,"institutionHeld":0,"latestPrice":3.76,"committee":0.866667,"eps":-0.201427,"divideRate":0,"volume":1391891,"delay":0,"ttmEps":-0.201427,"open":3.61,"prevYearClose":3.38,"prevWeekClose":3.51,"prevMonthClose":3.07,"prevQuarterClose":3.38,"fiveDayClose":3.4,"twentyDayClose":3.31,"sixtyDayClose":3.57,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613787730","title":"Clarity reports mCRPC patient reaches undetectable PSA and negative PSMA PET in SECuRE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787730?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:02","pubTimestamp":1771855322,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals reported an update from the Phase II cohort expansion of its SECuRE trial  evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer. The company said another participant receiving 8 GBq per cycle achieved undetectable PSA after the first cycle and had a negative PSMA PET scan after the second cycle; related adverse events were Grade 1 and no hematological or renal adverse events were observed to date. Clarity stated this is the fifth patient with undetectable disease by radiographic assessment following 67Cu-SAR-bisPSMA treatment, and also provided follow-up that a previously reported participant remains undetectable on PSMA PET one month after a fourth cycle. The results were presented in this announcement, and the SECuRE trial is continuing enrollment with planned recruitment completion in 2026 while Phase III planning is ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL50jZBy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2613084422","title":"Clarity Pharmaceuticals Says Prostate Cancer Trial Participant Achieves Undetectable Disease by Prostate-Specific Antigen; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613084422","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613084422?lang=en_us&edition=fundamental","pubTime":"2026-02-23 10:20","pubTimestamp":1771813245,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  said a participant with metastatic castration-resistant prostate cancer in the phase 2 group expansion phase of the SECuRE trial achieved undetectable disease as assessed by prostate-specific antigen and prostate-specific membrane antigen positron emission tomography, according to a Monday Australian bourse filing.The trial is evaluating the safety and efficacy of the company's targeted copper therapy-diagnostic product, copper-67-SAR-bisPSMA, for the potential treatment of prostate cancer.The participant achieved undetectable prostate-specific antigen levels seven weeks after his first cycle of copper-67-SAR-bisPSMA, the filing said. No disease was observed on prostate-specific membrane antigen positron emission tomography after receiving one more cycle of copper-67-SAR-bisPSMA. The participant showed mild related adverse effects, including altered taste, dry eyes, eye pain, fatigue, and salivary gland soreness. No blood-related or renal adverse effects were o","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CU6.AU","CPER","COPJ","MHGmain","QCmain","CPXR","BK7096","BK4535","XME"],"gpt_icon":0},{"id":"2612940145","title":"Why Clarity Pharmaceuticals (ASX:CU6) Is Up 14.5% After Standout Phase II PSMA Imaging Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612940145","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612940145?lang=en_us&edition=fundamental","pubTime":"2026-02-19 17:28","pubTimestamp":1771493310,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals recently announced that an abstract from its Co-PSMA Phase II investigator-initiated trial of 64Cu-SAR-bisPSMA has been accepted for oral presentation at the EAU Congress 2026, highlighting data from multiple studies including COBRA, PROPELLER and SECuRE.\nThe trial results indicated that 64Cu-SAR-bisPSMA more than doubled the number of prostate cancer lesions detected per patient versus standard-of-care imaging, with management plans altered in 44% of participants...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-145-after-standout","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-145-after-standout","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AI","BK4587","BK4023","BK7096","BK4551","BK4543","BK4585","BK4528","BK4588","CU6.AU"],"gpt_icon":0},{"id":"2612663774","title":"Clarity Pharmaceuticals (ASX:CU6) Valuation Check After New Co PSMA Abstract And Registrational Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2612663774","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612663774?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:14","pubTimestamp":1771334043,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing that an abstract on its dual targeting Co-PSMA agent has been accepted for oral presentation at the EAU Congress 2026, highlighting progress across multiple prostate cancer imaging trials.\nSee our latest analysis for Clarity Pharmaceuticals.\nThe EAU abstract sits alongside a strong run of short term momentum, with a 7 day share price return of 9.48% and a 30 day share price return of 7.83%. However, the year to date share...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-valuation-check-after-new-co","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-asxcu6-valuation-check-after-new-co","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CU6.AU","PRGS","LU2065732104.USD","BK4097","BK7096"],"gpt_icon":0},{"id":"2611748526","title":"Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Doubles Prostate Cancer Detection in Head-to-Head Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611748526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611748526?lang=en_us&edition=fundamental","pubTime":"2026-02-16 22:03","pubTimestamp":1771250600,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd. announced that data from the Co-PSMA Investigator-Initiated Trial , evaluating its diagnostic product 64Cu-SAR-bisPSMA in comparison to standard-of-care 68Ga-PSMA-11, will be presented at the European Association of Urology  Congress 2026. The study was conducted in 50 patients with biochemical recurrence of prostate cancer following radical prostatectomy. According to the released abstract, 64Cu-SAR-bisPSMA more than doubled prostate cancer lesion and patient detection rates compared to 68Ga-PSMA-11. Further data will be outlined following the oral presentation at EAU 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260216:nNDL9Bks3h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2611170618","title":"Clarity Pharmaceuticals Says Diagnostic Candidate Identifies Greater Number of Lesions Per Participant in Prostate Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2611170618","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611170618?lang=en_us&edition=fundamental","pubTime":"2026-02-16 11:12","pubTimestamp":1771211535,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  said that its copper-64-SAR-bisPSMA diagnostic candidate identified a \"statistically significant\" greater number of lesions per participant than standard-of-care gallium-68-PSMA-11 positron emission tomography /computed tomography  in the Co-PSMA investigator-initiated trial, according to a Monday Australian bourse filing.The phase two trial evaluated the performance of Clarity's diagnostic candidate, copper-64-SAR-bisPSMA, in comparison with gallium-68-PSMA-11 in 50 prostate cancer patients with biochemical recurrence of prostate cancer following radical prostatectomy, who were candidates for curative salvage therapy.The mean per-patient lesion was 1.3 for copper-64-SAR-bisPSMA PET/CT, compared with 0.5 for gallium-68-PSMA-11, with a difference of 0.8. In total, gallium-68-PSMA-11 identified 24 lesions across all participants, while copper-64-SAR-bisPSMA next-day imaging detected 63 lesions.At a per-patient level, gallium-68-PSMA-11 identified 36% of trial par","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","COPJ","MHGmain","BK4535","CPXR","XME","PET.AU","CU6.AU","CPER","QCmain","BK7096"],"gpt_icon":0},{"id":"2607507344","title":"Clarity Pharmaceuticals Ltd's (ASX:CU6) market cap dropped AU$145m last week; individual investors who hold 48% were hit as were institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2607507344","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607507344?lang=en_us&edition=fundamental","pubTime":"2026-01-31 07:10","pubTimestamp":1769814607,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Clarity Pharmaceuticals by individual investors implies that the general public...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-ltds-asxcu6-market-cap-dropped-au145","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-ltds-asxcu6-market-cap-dropped-au145","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2607950930","title":"Clarity Pharmaceuticals Posts Cash Position of AU$226.2 Million at End of December 2025 Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2607950930","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607950930?lang=en_us&edition=fundamental","pubTime":"2026-01-30 14:32","pubTimestamp":1769754776,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) reported on Friday a cash position of AU$226.2 million at Dec. 31, 2025, according to a Friday Australian bourse filing.Net operating cash flow reached AU$25.1 million for the eEcember 2025 quarter, per the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2604163777","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2604163777","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604163777?lang=en_us&edition=fundamental","pubTime":"2026-01-20 11:51","pubTimestamp":1768881077,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Tuesday.ARB : -12%, AU$28.544DMedical : -9%, AU$4.39Dateline Resources : -7%, AU$0.36Lynas Rare Earths : -7%, AU$15.15Clarity Pharmaceuticals : -6%, AU$3.06Perenti : -6%, AU$2.82Vulcan Energy : -6%, AU$4.04Austal : -6%, AU$8.06Orora : -6%, AU$2.13Pmet Resources : -5%, AU$0.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","LYC.AU","ARB.AU","BK7095","CU6.AU","BK7504","BK7115","BK7051","PRN.AU","VUL.AU","BK7507","ORA.AU","PMT.AU","BK7096","BK7094","BK7053","ASB.AU","4DX.AU","DTR.AU"],"gpt_icon":0},{"id":"2603766983","title":"Clarity Pharmaceuticals Advances SECuRE Trial After Positive Interim Results for 67Cu-SAR-bisPSMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2603766983","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603766983?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:02","pubTimestamp":1768485743,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd. has announced updates on its SECuRE clinical trial evaluating 67Cu-SAR-bisPSMA for the treatment of metastatic castration-resistant prostate cancer . Following an interim data review by the Safety Review Committee , the trial will proceed with its Cohort Expansion Phase  without modifications to the protocol. The interim results, based on data from nine participants as of November 25, 2025, indicate a favorable safety profile and promising efficacy for 67Cu-SAR-bisPSMA. Most participants in the trial were heavily pre-treated and had bone metastases. Clarity Pharmaceuticals intends to progress the product to a registrational Phase III study, with the aim of future commercialization. Results from the current phase have already been collected and assessed by the SRC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLb1x75k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2603625258","title":"Clarity Pharmaceuticals' Prostate Cancer Trial to Continue Without Changes to Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2603625258","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603625258?lang=en_us&edition=fundamental","pubTime":"2026-01-15 08:45","pubTimestamp":1768437955,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  is set to advance its SECuRE trial to the phase II cohort expansion phase with no changes to the protocol, following a recommendation by the safety review committee, according to a Thursday filing with the Australian bourse.The trial evaluates the company's targeted copper theranostic product, 67Cu-SAR-bisPSMA, for the treatment of prostate cancer, the filing said.The interim results assessed by the committee from nine participants who had evaluable data by Nov. 25, 2025, showed promising efficacy and a favorable safety profile for 67Cu-SAR-bisPSMA.The trial will continue enrollment in the cohort expansion phase, with recruitment completion expected this year, as per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":1},{"id":"2593477064","title":"Clarity Pharmaceuticals Co-PSMA Trial Results to Be Presented at EAU Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477064?lang=en_us&edition=fundamental","pubTime":"2025-12-24 22:02","pubTimestamp":1766584938,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire  on December 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDLW1kTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2593177695","title":"Clarity Pharmaceuticals Plans Phase 3 Registrational Trial for Neuroendrocine Tumor Diagnostic Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2593177695","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593177695?lang=en_us&edition=fundamental","pubTime":"2025-12-22 10:16","pubTimestamp":1766369772,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  plans to start a phase 3 registrational trial of its copper-64-Sartate diagnostic agent in patients with neuroendocrine tumors after it agreed on all key components of the proposed trial design with the US Food and Drug Administration in an end-of-phase meeting, according to a Monday Australian bourse filing.Recruitment for the trial is expected to start in 2026, and it will target around 70 participants.The final study results are intended to support an application to the US FDA for the approval of copper-64-Sartate as a new diagnostic imaging agent in neuroendocrine tumors, the filing said.Clarity Pharmaceuticals' shares fell nearly 1% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2593791171","title":"BUZZ-Australia's Clarity Pharma surges as US FDA approves trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2593791171","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593791171?lang=en_us&edition=fundamental","pubTime":"2025-12-22 08:06","pubTimestamp":1766361973,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharma surges as US FDA approves trial** Shares of Australia's Clarity Pharmaceuticals CU6.AX rise as much as 11.4% to A$3.72, their highest since November 25** Clinical stage","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL6N3XR08B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2593175091","title":"BRIEF-Clarity Pharmaceuticals To Commence Phase III Trial Of 64 Cu-Sartate In NETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2593175091","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593175091?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:32","pubTimestamp":1766356349,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals To Commence Phase III Trial Of 64 Cu-Sartate In NETSDec 22 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX:TO COMMENCE PHASE III TRIAL OF 64 CU-SARTATE IN NETSFurther company coverage: CU6.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nFWN3XR02X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2593752901","title":"Clarity Pharmaceuticals Ltd - to Commence Phase Iii Trial of 64 Cu-Sartate in Nets","url":"https://stock-news.laohu8.com/highlight/detail?id=2593752901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593752901?lang=en_us&edition=fundamental","pubTime":"2025-12-22 06:19","pubTimestamp":1766355576,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251221:nFWN3XR02X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2592137187","title":"BUZZ-Australia's Clarity Pharmaceuticals extends gains post Jefferies upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2592137187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592137187?lang=en_us&edition=fundamental","pubTime":"2025-12-19 12:26","pubTimestamp":1766118413,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharmaceuticals extends gains post Jefferies upgrade** Clarity Pharmaceuticals CU6.AX rises 1.4% to A$3.315; set for third straight session of gains** Stock has gained 13.5% s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL6N3XP08C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2592895521","title":"Clarity Can Continue to Tap Interesting Potential in Image Testing, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2592895521","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592895521?lang=en_us&edition=fundamental","pubTime":"2025-12-17 07:54","pubTimestamp":1765929250,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) can continue to unlock potential from NET diagnostics amid promising results from its specialized imaging testing trial for neuroendocrine tumors, Jefferies said in a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2592393461","title":"BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592393461","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592393461?lang=en_us&edition=fundamental","pubTime":"2025-12-17 03:13","pubTimestamp":1765912437,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies upgrades Australia's Clarity Pharma to 'buy' after latest trial** Jefferies upgrades Clarity Pharmaceuticals CU6.AX to 'buy' from 'hold', retains A$5.00 price target** Brokerage says Phase 2 trial data shows co's 64Cu-Sartate in patients with neuroendocrine tumours  identified more lesions than competition** After CU6's share price performance, we move to 'buy' - Jefferies** All 4 analysts recommend 'buy' or higher with median PT at A$7.70, as per LSEG-compiled data**YTD, shares down 30%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL6N3XM13C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2591340600","title":"Jefferies Upgrades Clarity Pharmaceuticals to Buy From Hold; Price Target is AU$5","url":"https://stock-news.laohu8.com/highlight/detail?id=2591340600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591340600?lang=en_us&edition=fundamental","pubTime":"2025-12-16 17:26","pubTimestamp":1765877174,"startTime":"0","endTime":"0","summary":"Jefferies Upgrades Clarity Pharmaceuticals to Buy From Hold; Price Target is AU$5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}